NASDAQ:GBIO Generation Bio (GBIO) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free GBIO Stock Alerts $3.70 +0.53 (+16.72%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$3.23▼$3.7350-Day Range$1.73▼$3.7052-Week Range$0.86▼$6.98Volume335,417 shsAverage Volume278,159 shsMarket Capitalization$245.96 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Generation Bio alerts: Email Address Generation Bio MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside116.2% Upside$8.00 Price TargetShort InterestHealthy2.62% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingSelling Shares$3,961 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.41) to ($1.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.91 out of 5 starsMedical Sector361st out of 939 stocksPharmaceutical Preparations Industry164th out of 422 stocks 3.2 Analyst's Opinion Consensus RatingGeneration Bio has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Generation Bio has a forecasted upside of 116.2% from its current price of $3.70.Amount of Analyst CoverageGeneration Bio has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.62% of the float of Generation Bio has been sold short.Short Interest Ratio / Days to CoverGeneration Bio has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Generation Bio has recently decreased by 11.81%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGeneration Bio does not currently pay a dividend.Dividend GrowthGeneration Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GBIO. Previous Next 4.1 News and Social Media Coverage News SentimentGeneration Bio has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Generation Bio this week, compared to 1 article on an average week.Search Interest15 people have searched for GBIO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added Generation Bio to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Generation Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,961.00 in company stock.Percentage Held by Insiders20.80% of the stock of Generation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.22% of the stock of Generation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Generation Bio are expected to grow in the coming year, from ($1.41) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Generation Bio is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Generation Bio is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneration Bio has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Generation Bio Stock (NASDAQ:GBIO)Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More GBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GBIO Stock News HeadlinesMarch 17, 2024 | finance.yahoo.comGBIO May 2024 7.500 callMarch 16, 2024 | finance.yahoo.comGBIO Apr 2024 5.000 callMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 8, 2024 | finance.yahoo.comGeneration Bio Co Reports Full Year and Q4 2023 Financial OutcomesMarch 7, 2024 | finanznachrichten.deGeneration Bio Co.: Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsMarch 6, 2024 | markets.businessinsider.comGBIO Stock Earnings: Generation Bio Misses EPS, Beats Revenue for Q4 2023March 6, 2024 | globenewswire.comGeneration Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | globenewswire.comGeneration Bio to Present at the 2024 TD Cowen Health Care ConferenceMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 25, 2024 | finance.yahoo.comGeneration Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth PlansFebruary 23, 2024 | benzinga.comGeneration Bio Stock (NASDAQ:GBIO), Short Interest ReportFebruary 21, 2024 | investing.comGeneration Bio Co (GBIO)February 21, 2024 | msn.comWhat Is Biohacking And Why Gen Z And Millennials Are Obsessed With ItFebruary 6, 2024 | bizjournals.comGeneration Bio ends Waltham lease but landlord fights backFebruary 3, 2024 | msn.comGeneration Bio Co. Ends Lease Citing Landlord BreachJanuary 30, 2024 | msn.comThe booming business of discovering your biological age: This tech company will measure it starting at $400 per yearJanuary 19, 2024 | benzinga.comGeneration Bio Stock (NASDAQ:GBIO) Dividends: History, Yield and DatesJanuary 17, 2024 | entrepreneur.comGeneration Z: Page 4January 14, 2024 | msn.com42 Tiny Observations About Gen Z Culture That Will Be Seriously Enlightening To Other GenerationsJanuary 3, 2024 | finance.yahoo.comGeneration Bio to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 7, 2023 | finance.yahoo.comCharles Rowland Bought 179% More Shares In Generation BioDecember 6, 2023 | finance.yahoo.comDirector Rowland Charles A Jr Acquires 342,960 Shares of Generation Bio Co (GBIO)November 30, 2023 | markets.businessinsider.comJMP Securities Keeps Their Hold Rating on Generation Bio (GBIO)November 29, 2023 | msn.comGeneration Bio cuts its payroll by 40 percent in latest restructuring moveNovember 29, 2023 | bizjournals.comModerna-partnered gene therapy firm to lay off 68, including two execsNovember 29, 2023 | marketwatch.comGeneration Bio Begins Strategic Reorganization, With 40% Headcount CutNovember 29, 2023 | finance.yahoo.comGeneration Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA PlatformsSee More Headlines Receive GBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Generation Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/27/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GBIO CUSIPN/A CIK1733294 Webgenerationbio.com Phone617-655-7500FaxN/AEmployees174Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+116.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,610,000.00 Net MarginsN/A Pretax Margin-2,144.51% Return on Equity-52.29% Return on Assets-31.80% Debt Debt-to-Equity RatioN/A Current Ratio6.83 Quick Ratio6.83 Sales & Book Value Annual Sales$5.90 million Price / Sales41.69 Cash FlowN/A Price / Cash FlowN/A Book Value$3.07 per share Price / Book1.21Miscellaneous Outstanding Shares66,480,000Free Float52,650,000Market Cap$245.98 million OptionableOptionable Beta2.70 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Cameron Geoffrey McDonough M.D. (Age 54)President, CEO & Director Comp: $939.09kDr. Matthew Norkunas M.B.A. (Age 45)M.D., Chief Financial Officer Comp: $611.11kDr. Matthew Stanton Ph.D. (Age 50)Chief Scientific Officer Comp: $654.83kDr. Mark D. Angelino Ph.D. (Age 51)Co-Founder Dr. Robert Kotin Ph.D. (Age 68)Co-Founder Ms. Antoinette Paone M.B.A. (Age 45)M.S., Chief Operating Officer Ms. Yalonda Howze J.D. (Age 51)Chief Legal Officer & Secretary Ms. Jasmin TowerChief Human Resources OfficerDr. Phillip Samayoa Ph.D. (Age 36)Chief Strategy Officer More ExecutivesKey CompetitorsImmutepNASDAQ:IMMPOvid TherapeuticsNASDAQ:OVIDMerrimack PharmaceuticalsNASDAQ:MACKZevra TherapeuticsNASDAQ:ZVRAOmerosNASDAQ:OMERView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 213,467 shares on 3/11/2024Ownership: 3.839%Goldman Sachs Group Inc.Bought 469,037 shares on 3/1/2024Ownership: 1.755%Price T Rowe Associates Inc. MDSold 528,529 shares on 2/16/2024Ownership: 10.481%GSA Capital Partners LLPBought 87,751 shares on 2/16/2024Ownership: 0.197%Barclays PLCBought 54,267 shares on 2/15/2024Ownership: 0.103%View All Insider TransactionsView All Institutional Transactions GBIO Stock Analysis - Frequently Asked Questions Should I buy or sell Generation Bio stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GBIO, but not buy additional shares or sell existing shares. View GBIO analyst ratings or view top-rated stocks. What is Generation Bio's stock price target for 2024? 6 brokerages have issued 12 month price objectives for Generation Bio's stock. Their GBIO share price targets range from $5.00 to $10.00. On average, they expect the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 116.2% from the stock's current price. View analysts price targets for GBIO or view top-rated stocks among Wall Street analysts. How have GBIO shares performed in 2024? Generation Bio's stock was trading at $1.65 at the beginning of 2024. Since then, GBIO stock has increased by 124.2% and is now trading at $3.70. View the best growth stocks for 2024 here. Are investors shorting Generation Bio? Generation Bio saw a drop in short interest in March. As of March 15th, there was short interest totaling 1,270,000 shares, a drop of 11.8% from the February 29th total of 1,440,000 shares. Based on an average trading volume of 327,000 shares, the days-to-cover ratio is currently 3.9 days. Currently, 2.6% of the shares of the stock are sold short. View Generation Bio's Short Interest. When is Generation Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our GBIO earnings forecast. How were Generation Bio's earnings last quarter? Generation Bio Co. (NASDAQ:GBIO) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.02. What other stocks do shareholders of Generation Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include DocuSign (DOCU), NVIDIA (NVDA), Overstock.com (OSTK), Boeing (BA), Pure Storage (PSTG), Mastercard (MA), QUALCOMM (QCOM), Riot Platforms (RIOT), Twilio (TWLO) and Enphase Energy (ENPH). When did Generation Bio IPO? Generation Bio (GBIO) raised $126 million in an initial public offering on Friday, June 12th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Generation Bio's major shareholders? Generation Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (10.48%), Price T Rowe Associates Inc. MD (10.48%), Vanguard Group Inc. (3.86%), Vanguard Group Inc. (3.84%), PFM Health Sciences LP (2.46%) and Goldman Sachs Group Inc. (1.75%). Insiders that own company stock include Antoinette Paone, Charles A Rowland Jr, Dannielle Appelhans, Donald William Nicholson, Douglas Kerr, Evan Spiegel, Geoff Mcdonough, Jason P Rhodes, Matthew Stanton, Phillip Samayoa and Venture Associates X L Atlas. View institutional ownership trends. How do I buy shares of Generation Bio? Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GBIO) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Generation Bio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.